Potential of antiviral drug oseltamivir for the treatment of liver cancer

Huang,Pei-Ju; Chiu,Chun-Ching; Hsiao,Min-Hua; Yow,Jia Le; Tzang,Bor-Show; Hsu,Tsai-Ching

doi:10.3892/ijo.2021.5289

Potential of antiviral drug oseltamivir for the treatment of liver cancer

Authors:
- Pei-Ju Huang
- Chun-Ching Chiu
- Min-Hua Hsiao
- Jia Le Yow
- Bor-Show Tzang
- Tsai-Ching Hsu
View Affiliations

Affiliations: Department of Family Medicine, Changhua Christian Hospital, Changhua 500, Taiwan, R.O.C., Department of Neurology and Department of Medical Intensive Care Unit, Changhua Christian Hospital, Changhua 500, Taiwan, R.O.C., Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung 402, Taiwan, R.O.C.
Published online on: December 2, 2021 https://doi.org/10.3892/ijo.2021.5289
Article Number: 109
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is a leading cause of cancer‑related mortality globally. Since hepatitis virus infections have been strongly associated with the incidence of liver cancer, studies concerning the effects of antiviral drugs on liver cancer have attracted great attention in recent years. The present study investigated the effects of two anti‑hepatitis virus drugs, lamivudine and ribavirin, and one anti‑influenza virus drug, oseltamivir, on liver cancer cells to assess alternative methods for treating liver cancer. MTT assays, wound healing assays, Τranswell assays, flow cytometry, immunoblotting, ELISA, immunofluorescence staining and a xenograft animal model were adopted to verify the effects of lamivudine, ribavirin and oseltamivir on liver cancer cells. Treatment with ribavirin and oseltamivir for 24 and 48 h significantly decreased the viability of both Huh-7 and HepG2 cells compared with that of THLE‑3 cells in a dose‑dependent manner. The subsequent investigations focused on oseltamivir, considering the more serious clinical adverse effects of ribavirin than those of oseltamivir. Significantly decreased migration and invasion were observed in both Huh-7 and HepG2 cells that were treated with oseltamivir for 24 and 48 h. In addition, oseltamivir significantly increased autophagy in Huh‑7 cells, as revealed by the significantly higher ratios of LC3‑II/LC3‑I, increased expression of Beclin‑1, and decreased expression of p62, whereas no significant increases in the expression of apoptosis‑related proteins, including Apaf‑1, cleaved caspase‑3, and cleaved PARP‑1, were detected. Notably, apoptosis and autophagy were significantly increased in HepG2 cells in the presence of oseltamivir, as revealed by the significant increases in the expression of Apaf‑1, cleaved caspase‑3, and cleaved PARP‑1, the higher ratios of LC3‑II/LC3‑I, the increased expression of Beclin‑1, and the decreased expression of p62. Additionally, significant inhibitory effects of oseltamivir on xenografted Huh‑7 cells in athymic nude mice were observed. The present study, for the first time to the best of our knowledge, reported the differential effects of oseltamivir on inducing liver cancer cell death both in vitro and in vivo and may provide an alternative approach for treating liver cancer.

View Figures

View References

1	Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular carcinoma. Nat Rev Dis Primers. 14:160182016. View Article : Google Scholar
2	Forner A, Reig M and Bruix J: Hepatocellular carcinoma. The Lancet. 391:1301–1314. 2018. View Article : Google Scholar
3	Kuo CN, Liao YM, Kuo LN, Tsai HJ, Chang WC and Yen Y: Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. J Formos Med Assoc. 119:1731–1741. 2020. View Article : Google Scholar
4	Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S and Talamini R: The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 20:353–357. 2009. View Article : Google Scholar
5	Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T and Tanabe KK: Risk factors, pathogenesis, and strategies for hepatocellular carcinoma prevention: Emphasis on secondary prevention and its translational challenges. J Clin Med. 9:38172020. View Article : Google Scholar :
6	Bosch FX, Ribes J, Cléries R and Díaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 9:191–211. 2005. View Article : Google Scholar
7	Dash S, Aydin Y, Widmer KE and Nayak L: Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment. J Hepatocell Carcinoma. 7:45–76. 2020. View Article : Google Scholar : PubMed/NCBI
8	Sung PS and Shin EC: Immunological mechanisms for hepatocellular carcinoma risk after direct-acting antiviral treatment of hepatitis C virus infection. J Clin Med. 10:2212021. View Article : Google Scholar :
9	Andrisani O: Epigenetic mechanisms in hepatitis B virus-associated hepatocellular carcinoma. Hepatoma Res. 7:122021.PubMed/NCBI
10	Ulcickas Yood M, Quesenberry CP Jr, Guo D, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Caldwell C and Manos MM: Incidence of hepatocellular carcinoma among individuals with heaptitis B virus infection identified using an automated data algorithm. J Viral Hepat. 15:28–36. 2008.
11	Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 127(5 Suppl 1): S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI
12	Nguyen VT, Law MG and Dore GJ: Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. J Viral Hepat. 16:453–463. 2009. View Article : Google Scholar : PubMed/NCBI
13	Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC and Lee YS: High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 67:945–952. 2018. View Article : Google Scholar
14	Pons F, Varela M and Llovet JM: Staging systems in hepatocellular carcinoma. HPB (Oxford). 7:35–41. 2005. View Article : Google Scholar
15	Mak LY, Cruz-Ramó V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, et al: Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 38:262–279. 2018. View Article : Google Scholar : PubMed/NCBI
16	Haxho F, Allison S, Alghamdi F, Brodhagen L, Kuta VE, Abdulkhalek S, Neufeld RJ and Szewczuk MR: Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma. Breast Cancer (Dove Med Press). 6:191–203. 2014.
17	Xu HZ, Liu YP, Guleng B and Ren JL: Hepatitis B virus-related hepatocellular carcinoma: Pathogenic mechanisms and novel therapeutic interventions. Gastrointest Tumors. 1:135–145. 2014. View Article : Google Scholar : PubMed/NCBI
18	Levy JM and Thorburn A: Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 131:130–141. 2011. View Article : Google Scholar
19	Chen C, Gao H and Su X: Autophagy-related signaling pathways are involved in cancer (Review). Exp Ther Med. 22:7102021. View Article : Google Scholar : PubMed/NCBI
20	Lee XC, Werner E and Falasca M: Molecular mechanism of autophagy and its regulation by cannabinoids in cancer. Cancers (Basel). 13:12112021. View Article : Google Scholar
21	Islam Khan MZ and Law HK: Cancer Susceptibility Candidate 9 (CASC9) promotes colorectal cancer carcinogenesis via mTOR-dependent autophagy and epithelial-mesenchymal transition pathways. Front Mol Biosci. 8:6270222021. View Article : Google Scholar
22	Khurana A, Roy D, Kalogera E, Mondal S, Wen X, He X, Dowdy S and Shridhar V: Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. Oncotarget. 6:36354–36369. 2015. View Article : Google Scholar : PubMed/NCBI
23	Liu X, Wu J, Fan M, Shen C, Dai W, Bao Y, Liu JH and Yu BY: Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells. Cell Death Dis. 9:10482018. View Article : Google Scholar : PubMed/NCBI
24	Zhang K, Zhou X, Wang J, Zhou Y, Qi W, Chen H, Nie S and Xie M: Dendrobium officinale polysaccharide triggers mitochondrial disorder to induce colon cancer cell death via ROS-AMPK-autophagy pathway. Carbohydr Polym. 264:1180182021. View Article : Google Scholar
25	Armando RG, Mengual Gómez DL and Gomez DE: New drugs are not enough-drug repositioning in oncology: An update. Int J Oncol. 56:651–684. 2020.PubMed/NCBI
26	Nunes M, Henriques Abreu M, Bartosch C and Ricardo S: Recycling the purpose of old drugs to treat ovarian cancer. Int J Mol Sci. 21:77682020. View Article : Google Scholar :
27	Hampson L, Maranga IO, Masinde MS, Oliver AW, Batman G, He X, Desai M, Okemwa PM, Stringfellow H, Martin-Hirsch P, et al: A single-arm, proof-of-concept trial of Lopimune (Lopinavir/Ritonavir) as a treatment for HPV-related pre-invasive cervical disease. PLoS One. 11:e01479172016. View Article : Google Scholar :
28	Beaucourt S and Vignuzzi M: Ribavirin: A drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr Opin Virol. 8:10–15. 2014. View Article : Google Scholar : PubMed/NCBI
29	Daughton CG and Ruhoy IS: Lower-dose prescribing: Minimizing 'side effects' of pharmaceuticals on society and the environment. Sci Total Environ. 443:324–337. 2013. View Article : Google Scholar
30	von Karstedt S, Montinaro A and Walczak H: Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 17:352–366. 2017. View Article : Google Scholar : PubMed/NCBI
31	Tan S, Liu X, Chen L, Wu X, Tao L, Pan X, Tan S, Liu H, Jiang J and Wu B: Fas/FasL mediates NF-kappaBp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis. Cell Death Dis. 12:4742021. View Article : Google Scholar
32	Alvarez-Meythaler JG, Garcia-Mayea Y, Mir C, Kondoh H and LLeonart ME: Autophagy takes center stage as a possible cancer hallmark. Front Oncol. 10:5860692020. View Article : Google Scholar
33	Buzun K, Gornowicz A, Lesyk R, Bielawski K and Bielawska A: Autophagy modulators in cancer therapy. Int J Mol Sci. 22:58042021. View Article : Google Scholar : PubMed/NCBI
34	Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T and Harris CC: p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis. 14:987–992. 1993. View Article : Google Scholar : PubMed/NCBI
35	Duffy MJ, Synnott NC and Crown J: Mutant p53 as a target for cancer treatment. Eur J Cancer. 83:258–265. 2017. View Article : Google Scholar
36	Braithwaite AW, Royds JA and Jackson P: The p53 story: Layers of complexity. Carcinogenesis. 26:1161–1169. 2005. View Article : Google Scholar
37	Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG and Foekens JA: Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer. 77:1130–1136. 1998. View Article : Google Scholar : PubMed/NCBI
38	Rossner P Jr, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M, et al: Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med. 13:3847–3857. 2009. View Article : Google Scholar
39	Guo JY and White E: Autophagy, metabolism, and cancer. Cold Spring Harb Symp Quant Biol. 81:73–78. 2016. View Article : Google Scholar
40	Shi K, An J, Qian K, Zhao X, Li F, Ma X, Wang Y and Zhang Y: p53 controls the switch between autophagy and apoptosis through regulation of PLSCR1 in sodium selenite-treated leukemia cells. Exp Cell Res. 389:1118792020. View Article : Google Scholar : PubMed/NCBI
41	Itakura E and Mizushima N: p62 Targeting to the autophagosome formation site requires self-oligomerization but not LC3 binding. J Cell Biol. 192:17–27. 2011. View Article : Google Scholar : PubMed/NCBI
42	Islam MA, Sooro MA and Zhang P: Autophagic Regulation of p62 is critical for cancer therapy. Int J Mol Sci. 19:14052018. View Article : Google Scholar :
43	Moscat J, Diaz-Meco MT and Wooten MW: Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci. 32:95–100. 2007. View Article : Google Scholar
44	Ichimura Y, Kominami E, Tanaka K and Komatsu M: Selective turnover of p62/A170/SQSTM1 by autophagy. Autophagy. 4:1063–1066. 2008. View Article : Google Scholar : PubMed/NCBI
45	Lin X, Li S, Zhao Y, Ma X, Zhang K, He X and Wang Z: Interaction domains of p62: A bridge between p62 and selective autophagy. DNA Cell Biol. 32:220–227. 2013. View Article : Google Scholar : PubMed/NCBI
46	Young MM, Takahashi Y, Khan O, Park S, Hori T, Yun J, Sharma AK, Amin S, Hu CD and Zhang J: Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. J Biol Chem. 287:12455–12468. 2012. View Article : Google Scholar : PubMed/NCBI
47	Sanz L, Diaz-Meco MT, Nakano H and Moscat J: The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1TRAF6 pathway. EMBO J. 19:1576–1586. 2000. View Article : Google Scholar
48	Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR and Ashkenazi A: Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 137:721–735. 2009. View Article : Google Scholar : PubMed/NCBI
49	Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D and Nicholson KG: Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: Systematic review and meta-analyses of randomised controlled trials. BMJ. 326:12352003. View Article : Google Scholar :
50	Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P and Straus SE: Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA. 282:1240–1246. 1999. View Article : Google Scholar
51	O'Shea LK, Abdulkhalek S, Allison S, Neufeld RJ and Szewczuk MR: Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. Onco Targets Ther. 7:117–134. 2014.
52	Kong F, Li N, Tu T, Tao Y, Bi Y, Yuan D, Zhang N, Yang X, Kong D, You H, et al: Hepatitis B virus core protein promotes the expression of neuraminidase 1 to facilitate hepatocarcinogenesis. Lab Invest. 100:1602–1617. 2020. View Article : Google Scholar : PubMed/NCBI